By Counterforce Health Team in Rystiggo (rozanolixizumab-noli) —

The Requirements Checklist to Get Rystiggo (rozanolixizumab-noli) Covered by Cigna in New Jersey

Answer Box: Getting Rystiggo (rozanolixizumab-noli) Covered by Cigna in New Jersey

Cigna requires prior authorization for Rystiggo (rozanolixizumab-noli) in New Jersey. You need confirmed AChR or MuSK antibody-positive generalized myasthenia gravis, MGFA Class II-IV symptoms, and documentation of inadequate response to standard therapies. Submit electronically via CoverMyMeds for fastest processing. If denied, you have 180 days for internal appeals, then access to New Jersey's Independent Health Care Appeals Program (IHCAP) through Maximus Federal Services—free external review with binding decisions.

First step today: Gather your antibody test results, MG-ADL score, and prior therapy records before your prescriber submits the PA request.

Table of Contents

  1. Who Should Use This Checklist
  2. Member & Plan Basics
  3. Clinical Criteria Requirements
  4. Coding and Billing Information
  5. Documentation Packet Essentials
  6. Submission Process
  7. Specialty Pharmacy Coordination
  8. After Submission: What to Expect
  9. Common Denial Prevention Tips
  10. Appeals Process in New Jersey
  11. Printable Quick-Reference Checklist

Who Should Use This Checklist

This guide helps New Jersey patients with generalized myasthenia gravis (gMG) and their healthcare providers navigate Cigna's approval process for Rystiggo (rozanolixizumab-noli). You'll need this if:

  • Your neurologist has prescribed Rystiggo for antibody-positive gMG
  • You have Cigna coverage (commercial, Medicare Advantage, or Medicaid managed care)
  • You're experiencing Class II-IV myasthenia gravis symptoms despite standard treatments
  • You've received a denial and need to appeal

Expected outcome: When properly documented, Rystiggo approvals typically process within 2-5 business days for electronic submissions. Appeals have strong success rates in New Jersey when medical necessity is clearly established.

Member & Plan Basics

Coverage Verification Checklist

□ Active Cigna coverage confirmed (check member portal or call 1-800-CIGNA24)
□ Plan type identified (commercial PPO/HMO, Medicare Advantage, or Medicaid)
□ Specialty drug benefits active (not subject to separate deductible in most NJ plans)
□ Prior authorization requirement confirmed (Rystiggo requires PA across all Cigna plans)

Note: Cigna manages specialty drugs through Express Scripts/Accredo. Your approval will route through their pharmacy benefit management system.

Clinical Criteria Requirements

Cigna's medical necessity criteria for Rystiggo require ALL of the following:

Primary Requirements

□ Age 12+ years (pediatric and adult indications covered)
□ Confirmed antibody-positive gMG:

  • Anti-acetylcholine receptor (AChR) antibodies OR
  • Anti-muscle-specific kinase (MuSK) antibodies
  • Lab documentation required with PA submission
    □ MGFA Class II-IV symptoms (Class I typically not covered)
    □ MG-ADL score ≥6 for patients 18+ years
    □ Inadequate response to standard therapies including:
  • Acetylcholinesterase inhibitors (pyridostigmine)
  • Corticosteroids or immunosuppressants
  • IVIG or plasmapheresis (if clinically appropriate)

Documentation Must Show

□ Persistent symptoms affecting daily activities (dysphagia, dyspnea, diplopia, weakness)
□ Stable concurrent therapies for ≥30 days before Rystiggo initiation
□ Weight-based dosing calculation (7 mg/kg subcutaneous weekly × 6 doses per cycle)

Coding and Billing Information

HCPCS and NDC Codes

Component Code Description Units
HCPCS J-Code J9333 Injection, rozanolixizumab-noli, 1 mg 1 unit = 1 mg
NDC Options 50474-0980-79 280 mg vial 280 units
50474-0981-83 420 mg vial 420 units
50474-0982-84 560 mg vial 560 units
50474-0983-86 840 mg vial 840 units

ICD-10 Diagnosis Codes

□ G70.00 - Myasthenia gravis without (acute) exacerbation
□ G70.01 - Myasthenia gravis with (acute) exacerbation

Administration Coding

□ CPT 96369 - Subcutaneous infusion, initial (≤1 hour)
□ Modifiers: JW (waste >10 mg), JZ (no waste)

Documentation Packet Essentials

Provider Clinical Note Must Include

□ Confirmed gMG diagnosis with antibody test results and dates
□ MGFA classification and current functional status
□ MG-ADL score (if applicable) with assessment date
□ Prior therapy history:

  • Medications tried, doses, duration
  • Clinical response or reasons for discontinuation
  • Dates of IVIG/plasmapheresis if used
    □ Current symptoms impacting quality of life
    □ Weight-based dosing rationale (patient weight, calculated dose)
    □ Treatment goals and monitoring plan

Medical Necessity Letter Components

A comprehensive letter should address:

  1. Clinical presentation: Specific symptoms and functional limitations
  2. Diagnostic confirmation: Antibody status and neurophysiology results
  3. Treatment history: Step-through of prior therapies with outcomes
  4. Medical literature support: FDA approval basis and clinical trial data
  5. Dosing justification: Weight-based calculation and cycle frequency
  6. Safety monitoring: Plan for adverse event management

Required Attachments

□ Antibody test results (AChR or MuSK positive)
□ Recent clinic notes (within 90 days)
□ Prior therapy documentation (prescription records, infusion logs)
□ MGFA assessment and MG-ADL scoring (if performed)
□ Laboratory results supporting current status

Submission Process

Primary method: CoverMyMeds Portal

  • Search "Cigna Rystiggo" for drug-specific form
  • Complete all required fields to avoid auto-rejection
  • Upload supporting documents as PDF attachments
  • Processing time: 2 business days standard, 24 hours expedited

Alternative Submission Methods

Phone: 1-800-882-4462 (1-800-88.CIGNA) for verbal requests
Fax: Use state-specific forms (verify current fax number through CoverMyMeds)

Common Rejection Triggers to Avoid

□ Missing antibody documentation - most frequent cause of denial
□ Incomplete prior therapy history - must show adequate trials
□ Wrong ICD-10 codes - use G70.00 or G70.01 specifically
□ Calculation errors - verify mg/kg dosing matches patient weight
□ Outdated forms - always use current year PA form version

Specialty Pharmacy Coordination

Cigna's Preferred Network

Rystiggo typically ships through Accredo Specialty Pharmacy (Cigna's preferred vendor):

  • Phone: 1-800-803-2523
  • Transfer process: Automatic after PA approval
  • Delivery: Refrigerated shipping, signature required

Patient Preparation Steps

□ Confirm delivery address and availability for signature
□ Review injection training materials from manufacturer
□ Schedule follow-up with prescriber within 2 weeks of first dose
□ Insurance verification completed by specialty pharmacy

After Submission: What to Expect

Timeline and Status Tracking

Milestone Standard Timeline Expedited Timeline
Initial Review 2 business days 24 hours
Additional Info Request 3-5 days (if needed) 24-48 hours
Final Determination 5-7 business days total 48-72 hours

Confirmation and Next Steps

□ Record confirmation number from submission
□ Check status via Cigna provider portal or phone
□ Document all communications (dates, reference numbers, outcomes)
□ Specialty pharmacy contact initiated within 24-48 hours of approval

Common Denial Prevention Tips

Five Critical Pitfalls and Solutions

1. Insufficient Antibody Documentation

  • Problem: Generic "myasthenia gravis" without antibody specificity
  • Solution: Include specific AChR or MuSK antibody titers with lab reference ranges

2. Missing Step Therapy Documentation

  • Problem: No evidence of prior standard therapy trials
  • Solution: Document pyridostigmine use, steroid trials, or contraindications with dates and outcomes

3. Incorrect Dosing Calculations

  • Problem: Dosing doesn't match 7 mg/kg weekly protocol
  • Solution: Show calculation: [patient weight kg] × 7 mg/kg = dose per injection

4. Outdated Clinical Information

  • Problem: Clinic notes older than 90 days
  • Solution: Provide recent assessment confirming current symptom severity

5. Incomplete Functional Assessment

  • Problem: Missing MGFA class or functional impact description
  • Solution: Document specific daily living limitations and MGFA classification

Appeals Process in New Jersey

If your initial PA request is denied, New Jersey offers robust appeal rights:

Internal Appeals with Cigna

Level 1 Appeal

  • Deadline: 180 days from denial date
  • Decision timeline: 30 days
  • How to file: Cigna appeals portal or written request

Level 2 Appeal

  • Deadline: 60 days from Level 1 decision
  • Decision timeline: 30 days
  • Review: Different medical director reviews case

New Jersey External Review (IHCAP)

After completing internal appeals, you can access the Independent Health Care Appeals Program administered by Maximus Federal Services:

Key Benefits:

  • Free to patients (Cigna pays all costs)
  • Binding decisions (Cigna must comply if overturned)
  • Medical expert review by appropriate specialists
  • Strong success rates for well-documented cases

Filing Requirements:

  • Deadline: 4 months from final internal denial
  • Eligibility: Fully insured NJ plans (not self-funded ERISA plans)
  • Submit to: Maximus Federal Services via njihcap.maximus.com
  • Timeline: 5 days preliminary review, 45 days final decision (48 hours if expedited)

Contact Information:

  • IHCAP Hotline: 1-888-393-1062
  • NJ DOBI Consumer Line: 1-800-446-7467

When Counterforce Health helps patients navigate complex specialty drug appeals like Rystiggo, we often see that New Jersey's external review process provides an excellent safety net for appropriately documented cases. The state's requirement for independent medical expert review means that clinical evidence—not just insurance company policies—drives the final coverage decision.

From our advocates: In a recent composite case involving a specialty neurologic medication similar to Rystiggo, the patient's initial denial was overturned at the New Jersey external review level when we provided comprehensive antibody documentation and step therapy history. The key was demonstrating clear medical necessity through objective clinical measures rather than just symptom descriptions. While outcomes vary by individual case, thorough documentation significantly improves appeal success rates.

Printable Quick-Reference Checklist

Before Submitting PA Request

□ Confirmed AChR or MuSK antibody-positive test results
□ MGFA Class II-IV documentation
□ MG-ADL score ≥6 (if age 18+)
□ Prior therapy documentation (pyridostigmine, steroids, IVIG/PLEX)
□ Current weight for dosing calculation
□ Recent clinic notes (within 90 days)
□ ICD-10 code G70.00 or G70.01

During Submission

□ Electronic submission via CoverMyMeds preferred
□ Complete all required form fields
□ Attach all supporting documents
□ Record confirmation number
□ Set calendar reminder for status check in 3 days

If Denied

□ Review denial reason carefully
□ Gather additional documentation to address specific concerns
□ File Level 1 appeal within 180 days
□ Consider peer-to-peer review request
□ Prepare for Level 2 appeal if needed
□ Document all communications with reference numbers

For External Review (if needed)

□ Complete both internal appeal levels first
□ File IHCAP request within 4 months of final denial
□ Submit through Maximus Federal Services
□ Include all denial letters and medical records
□ Contact IHCAP hotline (1-888-393-1062) with questions

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions depend on individual circumstances and plan specifics. Always consult with your healthcare provider about treatment options and contact your insurance company directly for the most current policy information. For additional help with insurance appeals in New Jersey, contact the Department of Banking and Insurance Consumer Hotline at 1-800-446-7467.

Need help navigating complex prior authorization requirements or appealing a denial? Counterforce Health specializes in turning insurance denials into targeted, evidence-backed appeals by analyzing denial letters, plan policies, and clinical notes to create comprehensive rebuttals aligned with each payer's specific requirements.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.